Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 21, 2022Nature CommunicationsOpen Access

Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic BCL2L12

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZixiang WangSWShourong WangJQJunchao Qin

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Wang et al. (2022) studied this question.

synapsesocial.com/papers/69debe73499d77a496b0cb72https://doi.org/10.1038/s41467-022-34042-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1spliceR: an R package for classification of alternative splicing and prediction of coding potential from RNA-seq data2014 · 119 citations
  2. 2Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma2008 · 146 citations
  3. 3Splicing factor BUD31 promotes ovarian cancer progression through sustaining the expression of anti-apoptotic <i>BCL2L12</i>2022 · 1 citations
  4. 4STAR: ultrafast universal RNA-seq aligner2012 · 58,263 citations
  5. 5Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA22021 · 70 citations